C

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.24
    -0.81 (-4.75%)

    Market Cap: $610.97M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(5/10)
    Avg Surprise
    -19.76%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.45
    Range$-0.51 - $-0.40
    7 analysts
    EPS Revisions
    1
    0
    7d
    7
    0
    30d
    EPS Estimate Drift
    90d ago$-0.43+5.7%
    60d ago$-0.43+5.7%
    30d ago$-0.43+5.7%
    7d ago$-0.46-0.2%
    Current$-0.45
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.12
    Range$-0.40 - $0.47
    7 analysts
    Revenue Consensus
    $7M
    Range$0 - $30M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.12---
    Sep 26EST
    		-$-0.45---
    Jun 26
    Reported Jul 30
    		$-0.40$-0.46+13.04%Beat+35.5%
    Mar 26
    Reported May 5
    		$-0.39$-0.53+26.42%Beat+37.1%
    Dec 25
    Reported Mar 5
    		$-0.49$-0.65+24.62%Beat+12.5%
    Sep 25
    Reported Oct 30
    		$-0.45$-0.46+2.17%Beat-12.5%
    Jun 25
    Reported Aug 5
    		$-0.62$-0.41-51.22%Miss-59.0%
    Mar 25
    Reported May 14
    		$-0.62$-0.57-8.77%Miss+82.5%
    Dec 24
    Reported Mar 6
    		$-0.56$-0.43-30.23%Miss+61.1%
    Sep 24
    Reported Nov 6
    		$-0.40$-0.42+4.76%Beat-
    Jun 24
    Reported Aug 13
    		$-0.39$-0.35-11.43%Miss-
    Mar 24
    Reported May 16
    		$-3.55$-1.33-166.92%Miss-
    Dec 23
    Reported Feb 28
    		$-1.44$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-9.39EV/EBITDA20.76x
    Price/FCF-11.38xFCF Yield-8.79%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-28.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage90.25x
    Current Ratio37.17xQuick Ratio37.17x
    Trading Statistics
    Beta0.74Avg Volume561.91K
    52-Week High$17.5152-Week Low$8.60

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.50
    SMA 20$15.74
    SMA 50$14.98
    SMA 200$13.39
    EMA 10$16.44
    EMA 20$15.95
    EMA 50$15.08
    EMA 200$13.18

    MACD

    Line: 0.61Signal: 0.52Hist: 0.09

    ADX

    ADX: 24.5+DI: 21.8-DI: 15.3

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down4.0
    PSAR$15.08

    Bollinger Bands

    Upper Band$17.80
    Lower Band$13.68
    %B Position2615%(Upper)
    Band Width0.62

    RSI (14-Day)

    Neutral
    54.6

    Momentum Oscillators

    Stoch %K80.5
    Stoch %D85.6
    Williams %R-37.2
    ROC (10d)11.8%
    Momentum1.71
    CCI (20d)51.8
    MFI (14d)44.9

    Volatility Measures

    ATR (14d)$1.01(6.2%)
    StdDev (20d)1.03
    Hist Vol63.9%(High)

    Volume Flow

    VWAP$16.41
    OBV17.5M
    AD Line1.5M
    CMF (20d)-0.101

    Volume Metrics

    Avg Vol (20d)574.3K
    Vol Ratio0.6x
    VWMA (20d)$15.45

    Pivot Points

    R3$17.79
    R2$17.60
    R1$17.32
    Pivot Point$17.13
    S1$16.85
    S2$16.66
    S3$16.38

    Advanced Oscillators

    TSI18.72
    Ultimate Osc52.7
    KST94.44

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$242,000$0$0$0$0$0
    Cost of Revenue$0$0$85,000$0$0$0$121,000$0$0$0$37,000$0
    Gross Profit$0$0$-85,000$0$0$0$121,000$0$0$0$-37,000$0
    Operating Expenses$17.43M$16.90M$17.11M$14.93M$17.90M$18.11M$17.05M$12.97M$10.94M$9.93M$9.68M$8.07M
    R&D$12.70M$11.65M$12.76M$10.99M$14.06M$13.71M$13.02M$9.73M$7.90M$7.78M$8.01M$6.50M
    SG&A$4.73M$5.26M$4.36M$3.94M$3.84M$4.40M$4.03M$3.25M$3.04M$2.15M$1.66M$1.57M
    Operating Income$-17,428,000$-16,904,000$-17,115,000$-14,932,000$-17,902,000$-18,110,000$-17,046,000$-12,974,000$-10,944,000$-9,930,000$-9,676,000$-8,069,000
    Interest Income$2.34M$2.50M$2.01M$1.96M$2.03M$2.25M$2.53M$2.74M$2.00M$1.64M$1.79M$1.74M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-15,154,000$-14,456,000$-15,156,000$-12,792,000$-16,040,000$-15,990,000$-14,565,000$-10,267,000$-9,009,000$-8,417,000$-7,930,000$-6,369,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$-161,000$-118,000
    Net Income$-15,154,000$-14,456,000$-15,156,000$-12,792,000$-16,040,000$-15,990,000$-14,565,000$-10,267,000$-9,009,000$-8,417,000$-7,769,000$-6,251,000
    EBITDA$-18,213,000$-17,273,000$-17,184,000$-14,664,000$-18,397,000$-18,447,000$-18,082,000$-13,729,000$-12,019,000$-11,015,000$-10,882,000$-9,539,000
    EBIT$-17,496,000$-16,961,000$-17,166,000$-14,749,000$-18,069,000$-18,240,000$-17,092,000$-13,008,000$-11,010,000$-10,053,000$-9,720,000$-8,105,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CTNM

    News

    Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and SpaceX (SPCX)

    This article provides analyst insights on two NA sector companies: Rapport Therapeutics, Inc. (RAPP) and SpaceX (SPCX). William Blair maintained a Buy rating for Rapport Therapeutics, while DZ BANK AG downgraded SpaceX to Sell. The article also includes price targets and analyst consensus ratings for both companies.

    The Globe and Mail•8/21/26•
    Somewhat-Bullish

    Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing

    Balyasny Asset Management and its affiliated entities have reported a 7.14% beneficial ownership stake in Contineum Therapeutics (CTNM) Class A common stock through a Schedule 13G/A filing. This equates to 2,335,550 shares, with sole voting and dispositive power, based on 32,723,877 shares outstanding as of April 30, 2026. The filing indicates that this position is held in the ordinary course of business and not for influencing control of the issuer.

    Stock Titan•8/14/26•
    Neutral

    Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

    Three analysts have issued bullish sentiments on healthcare companies Immunic (IMUX), Legend Biotech (LEGN), and Sagimet Biosciences, Inc. Class A (SGMT). William Blair reiterated a Buy rating on Immunic, H.C. Wainwright reiterated a Buy on Legend Biotech with a $65.00 price target, and Wedbush maintained a Buy rating on Sagimet Biosciences, Inc. Class A with a $28.00 price target. The consensus ratings suggest Strong Buy for Immunic and Sagimet, and Moderate Buy for Legend Biotech.

    The Globe and Mail•8/13/26•
    Somewhat-Bullish

    Contineum Therapeutics CEO Stengone sells $40,029 of common stock

    Carmine N. Stengone, CEO of Contineum Therapeutics, Inc. (NASDAQ:CTNM), sold 2,500 shares of the company's common stock for $40,029 on August 3, 2026, while also exercising stock options for an equal number of shares. The transactions were part of a pre-arranged 10b5-1 trading plan and occurred with the stock near its 52-week high after a significant gain.

    Investing.com•8/4/26•
    Neutral

    Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise

    Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 2,500 shares at $1.01 per share and subsequently sold these 2,500 shares at a weighted average price of $16.0116. These transactions, executed under a Rule 10b5-1 trading plan adopted in September 2025, resulted in an approximate pre-tax spread of $38,000. After the transactions, Stengone retains 276,930 outstanding stock options and 17,217 shares of Class A Common Stock.

    Stock Titan•8/4/26•
    Neutral

    Frequently Asked Questions About CTNM

    Does CTNM pay dividends?
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) does not currently pay a regular dividend.
    What is CTNM's market cap?
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a market capitalization of $610.97M with a current stock price of $16.24.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In